Optoacoustic sensors for early disease detection and monitoring

Projektinformationen

RSENSE4Health

ID Finanzhilfevereinbarung: 101034883

DOI

10.3030/101034883

Projekt abgeschlossen

EK-Unterschriftsdatum 16 März 2021

Startdatum 1 September 2021

Enddatum 31 Mai 2023

Finanziert unter

• EXCELLENT SCIENCE - Future and Emerging Technologies (FET)

Gesamtkosten

Keine Daten

EU-Beitrag

€ 100 000,00

Koordiniert durch

TECHNISCHE UNIVERSITAET MUENCHEN
Germany

Periodic Reporting for period 1 - RSENSE4Health (Optoacoustic sensors for early disease detection and monitoring)

Berichtszeitraum: 2021-09-01 bis 2023-05-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Diabetes and cardiovascular disease (CVD) are responsible for the majority of the morbidity and mortality in the EU. However, to date there is no technology available that offers a non-invasive and portable way for disseminated measurements of disease effects on the systemic level or for monitoring disease progression from early development stages. RSENSE4Health aims to accelerate the exploitation of a powerful, portable optoacoustic sensor, developed under the RSENSE project, an EU project funded under the FET programme. For the first time, this sensor can non-invasively detect the systemic effects of diabetes and CVD developing in home environments – a performance not available to any other sensors. With more than one billion potential users, this technology has an enormous market and global impact potential. To bring this innovation to the market, RSENSE4Health will sharpen product specifications with stakeholder interviews, solidify patent strategy, and identify an optimal regulatory and business roadmap in order to accelerate company spin-off and product launch.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

A market analysis was performed to define product specifications for market deployment; develop an implementation roadmap; and identify regulatory barriers and requirements. The work carried out on RSENSE4Health was based on the optoacoustic medical sensor developed through RSENSE Project (GA #862811). We have successfully identified pathways towards a health insurance reimbursement and confirmed interest by key opinion leaders and other relevant stakeholders in our product. A market entry strategy was developed.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

RSENSE4Health promises to drive healthcare transition by providing so far inaccessible diagnostic biomarkers, e.g. microvessel parameters linked to diabetes and CVD. For the first time, this performance can enable remote diagnostics and therapy monitoring of these diseases, beyond the wellness use of current wearables.
When the sensor is ready and launched, we foresee the following socio-economic impacts:
- Our innovation will contribute to strengthen the position of the EU as global market leader in healthcare provision and MedTech development maintaining independence from other technologies and countries
- Ease the burden of disease of diabetes and CVD
- Longitudinal Precision Medicine and personalised therapy
- Reduce healthcare costs
- Improve healthcare access

RSENSE4Health logo